The U.S. Food and Drug Administration on Thursday approved Gilead Sciences's antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.
Americans need to be prepared for the possibility that they may feel a little unwell. After you get a coronavirus vaccine, if one is authorized, you may experience some negative side effects. The CDC met to discuss whether to recommend the use of any Covid-19 vaccines. The US Food and Drug Administration or FDA is the agency that might authorize one. Volunteers in vaccine trials have reported they frequently feel flu-like effects after getting vaccinated.
On Monday, US stocks rose. AstraZeneca said its COVID-19 vaccine candidate demonstrated an average efficacy rate of 70%. This is the third COVID-19 vaccine said to have surpassed the Food and Drug Administration's requirement of 50% effectiveness. S&P 500: 3,580.82, up 0.7% Dow Jones industrial average: 29,473.41, up 0.7% (210 points) Nasdaq composite: 11,929.04, up 0.6%
There are currently two COVID-19 vaccines promising results from their Phase 3 trials. Moderna announced that its vaccine was 94.5% effective. Pfizer/BioNTech announced that their vaccine was 95% effective. How long will it take for all Americans to be vaccinated? If the FDA approves the vaccine, Business Insider says first responders and vulnerable populations will receive vaccines through March.
The FDA approved remdesivir as a treatment for severe COVID-19 cases last month. This is after granting emergency authorization in May, reports Business Insider. But on Thursday, the WHO announced it will not recommend the drug's use for COVID-19 patients. "There is currently no evidence that it improves survival or the need for ventilation," the organization said. Remdesivir was the first coronavirus treatment to receive emergency authorization from the FDA.
Lock hardware business in Aligarh suffered setback due to lockdown. In the month of July, situation between India and Nepal further deepened their woes. While industries are gradually coming on track, Extant COVID crisis continues to diminish hopes. "Due to restrictions in some states it's difficult for our agents and they can't collect demands. Sellers think they won't be able to sell, so they're neither buying raw material nor supplying to us," said C Sharma, Tala Nagri Industrialist Association's Chairman.
[NFA] The White House coronavirus task force coordinator Dr. Deborah Birx on CBS’s ‘Face The Nation’ Sunday said she is increasingly concerned about a potential new spike in COVID-19 infections after Thanksgiving, as lawmakers continue to stall on legislation that could be crucial to vaccine distribution. Gavino Garay has more.